The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades

Since the first clinical application of analgesia following spinal anticholinesterase by 1940’s, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 \( \mu \)g, due to side-effects. Conversely, epidural neostigmine has been evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects.

Key words: Epidural neostigmine, pain, review, spinal neostigmine

The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades

Gabriela Rocha Lauretti

Department of Biomechanics, Medicine and Rehabilitation of Locomotor Members, Teaching Hospital, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

Address for correspondence:
Prof. Gabriela Rocha Lauretti,
Rua Maestro Joaquim Rangel, 644, CEP 14025-610 Ribeirão Preto, São Paulo, Brazil.
E-mail: grlauret@fmrp.usp.br

INTRODUCTION

The text focus on the natural evolution of neostigmine’s applicability in pain relief. The story starts by anecdotal case reports of analgesia following spinal anticholinesterase by 1940’s. 30 years later the interest in anti-nociception by anticholinesterase agents were restarted by Pleuvry and Tobias, in England, culminating with its demonstration of spinal analgesia in animals by 1980’s. The search carried on in volunteers and finally with different sorts of clinical randomized double-blind studies, which started by 1990’s. Firstly, the differences between patients and volunteers, subsequently the dose-dependent analgesia and side-effects of spinal neostigmine; and finally the surprise of analgesia after its epidural administration were described. When one analyze the past two decades, intrathecal (IT) doses of neostigmine in humans ranged from 750 to 1 \( \mu \)g. Due to side-effects the dose was substantially decreased. As a consequence of the small dose, neostigmine should be applied only as part of multimodal spinal analgesia and further clinical trials are still needed. Conversely, epidural neostigmine may be evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects.

HISTORY OF THE CLINICAL APPLICATION OF ANTICHOLINESTERASE AGENTS AS ANALGESICS: FROM ANECDOTAL REPORTS OF PATIENTS, THROUGH ANIMAL DATA, TO A PROPER STUDY IN VOLUNTEERS (1933-1985)

Eighty years have elapsed since the first citation of the analgesic effects of anticholinesterase agents, when Pellandra[1] observed that intravenous administration of the anticholinesterase drug physostigmine produced analgesia in human beings. In 1942, Kremer described the use of cholinergic and anticholinesterase agents by the IT route to induce analgesia in hemiplegic patients.[2] By 1945, the systemic analgesic action of physostigmine and neostigmine and of the opioid morphine was evaluated in patients by Flodmark and Wrammer.[3]

In the seventies, the antinociceptive effect of cholinergic drugs and a link with opioid analgesia was emphasized.[4,5] Pleuvry and Tobias, in England, were the ones to restart the interest in the cholinergic mechanism of pain.[4] In 1981, autoradiography studies demonstrated the existence of muscarinic binding sites in the substantia gelatinosa, in laminae III and V of the dorsal gray matter of the medulla six, coinciding with the binding sites for opioids. By 1985, Yaksh et al. described the antinociception in rat and cat

Access this article online

Quick Response Code:
Website: www.saudija.org
DOI: 10.4103/1658-354X.146319

ABSTRACT

Since the first clinical application of analgesia following spinal anticholinesterase by 1940’s, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 \( \mu \)g, due to side-effects. Conversely, epidural neostigmine has been evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects.

Key words: Epidural neostigmine, pain, review, spinal neostigmine
following spinal cholinomimetic drugs. Petersson et al., impressed by the potential analgesic characteristics of anticholinesterase agents, confirmed that intravenous administration of physostigmine induced immediate, although short-lasting, post-operative analgesia in patients submitted to various types of surgical procedures. In the nineties, a systematic approach to determine potential neurotoxicity of IT methyl sulfate neostigmine revealed safety after histological, physiologic and behavioral testing in rat, dog and sheep, and neostigmine also did not influence the neurotoxicity of lidocaine in vitro.

Spinal cord histological examination in sheep and rat also revealed the safety of paraben-and glucose-containing IT neostigmine. Subsequent clinical testing in human volunteers and patients with terminal cancer refractory to conventional therapy motivated further clinical trials, that will be detailed in succeeding sections.

**SPINAL/EPIDURAL ANALGESIC ACTION OF NEOSTIGMINE**

**Pharmacokinetics**

Neostigmine was introduced in 1931. It is a reversible inhibitor of the enzyme cholinesterase, which results in an increased concentration of the acetylcholine (Ach) neurotransmitter. However, due to its hydrophilic nature (presence of a functional quaternary ammonia), it does not cross the duramater, what justified the interest of its applicability as IT analgesic until early 1990’s. After spinal administration of neostigmine, Ach concentration increased from <20 pmol/ml at baseline to >100 pmol/ml within 15 min, while plasma concentration was approximately 5 ng/ml. Concentration in cerebrospinal fluid could be measured for 24 h. The pharmacokinetic of IT neostigmine was best described by a triexponential function with an absorption phase. Individual predicted concentrations varied 100-fold. It was characterized by prolonged distribution (t1/2α = 23 min) and elimination (t1/2β = 260 min). No study to date has evaluated the pharmacokinetics of epidural neostigmine.

**Mechanisms of IT neostigmine analgesia**

The analgesia resulting from spinal administration of neostigmine may be due to the increased concentration of Ach and the consequent binding to M1, M3, M2 and M4 muscarinic and to nicotinic receptors. It was demonstrated that activation of spinal muscarinic type-2 receptors suppressed spinal gamma-amino butyric acid-B (GABA-B) receptor input and that this disinhibiting mechanism ultimately lead to the release of adrenal catecholamines and subsequent reduction in peripheral inflammation. Spinal cord stimulation was also associated with the activation of the cholinergic system in the dorsal horn and mediated via muscarinic receptors, particularly M4, while nicotinic receptors appeared not to be involved.

The existence of a difference in the predominance of different types of cholinergic receptors between males and females has been suggested, although controversial. While in males muscarinic receptors may be responsible for the antinociceptive effect, the participation of muscarinic and nicotinic receptors was demonstrated in females.

The spinal cholinergic interneurons may be activated by serotoninergic and noradrenergic descending pathways that inhibit pain. Gabaergic interneurons have muscarinic receptors in the terminal axons and in somatodendritic sites and activation of these receptors increase the excitability of inhibitory interneurons, enhancing the release of GABA in the substantia gelatinosa. This inhibitory gabaergic system is also controlled by cholinergic neurons located deeply in the posterior horn of the spinal medulla. The activation of muscarinic receptors inhibits spinal dorsal horn projection neurons, suggesting a partial

---

**Figure 1:** Cholinergic pathways at the dorsal horn
role of GABA-B receptors in normal or in diabetic rats. In addition spinal neostigmine administration resulted in reduced substance P and there appears to be unidirectional cross-tolerance between morphine and neostigmine. In cats, spinal neostigmine showed antinociceptive effect and this inhibition was only partially mediated by cholinergic mechanism.

Similarly, IT neostigmine may act in different ways on phase and tonic pain, may interact synergistically with \( \alpha \)-agonists, nitric oxide and muscimol. Neostigmine also stimulated the expression of HLA-DR and interleukin (IL) triggered by long potential retraction in rats, alleviating post-thoracotomy pain. Spinal administration of neostigmine to mice resulted in synergistic or supra-additive effects when the drug was used in combination with ketoprofen, paracetamol or diclofenac. However, only an additive analgesic effect occurred when neostigmine was combined with meloxicam and pyroxicam.

However, only an additive analgesic effect occurred when neostigmine was combined with meloxicam and pyroxicam. Ach is a major neurotransmitter but also an important signaling molecule in neuron-glia interactions. Expression of Ach receptors has been reported in several glial cell populations, including oligodendrocytes, which may be activated in chronic pain states. Recently, an electron microscopy analysis demonstrated that cholinergic boutons are presynaptic to the dorsal horn neurons as well as to the terminals of sensory primary afferents, suggesting that they are likely to modulate incoming somatosensory information. The authors are suggested that this newly identified dorsal horn cholinergic system in monkeys was the source of the Ach involved in the analgesic effects of epidural neostigmine.

Related to chronic pain, an increased expression of the \( \alpha_3 \) and \( \alpha_5 \) nicotinic subunits may contribute to the mechanical hypersensitivity observed following spinal nerve ligation, and IT neostigmine reduced allodynia secondary to rib-retraction in rats, alleviating post-thoracotomy pain. Neostigmine also stimulated the expression of HLA-DR (human leukocyte antigen-DR-microglial marker) and the production of tumor necrosis factor alpha (TNF-\( \alpha \)) at dendritic cells while inhibiting the production of TNF-\( \alpha \) and interleukin (IL) triggered by long potential stimulation, supporting the existence of the loop through which Ach modulates the function of dendritic cells.

Mechanisms of epidural neostigmine analgesia

Epidural neostigmine analgesia seems to be a result of central rather than peripheral action. In patients undergoing surgery, epidural neostigmine resulted in analgesia after the administration of a ten-fold lower dose (1 \( \mu \)g/kg), when compared to knee intraarticular administration, suggesting a central effect. Epidural neostigmine acts on the enzymes acetylcholinesterase and butyrylcholinesterase expressed in the meninges that cover the spinal cord. Another aspect to be considered is the possible direct action of neostigmine as a muscarinic agonist, in addition to the indirect stimulation of the release of the second intracellular messenger, nitric oxide and suppression of cFos expression.

DOSE-RELATED EFFECTS OF NEOSTIGMINE

In 1995, Hood and Eisenach published the phase I safety assessment of IT neostigmine methylsulfate in humans, when 28 healthy volunteers received IT neostigmine (50-750 \( \mu \)g). The authors demonstrated a dose-dependent incidence of analgesia and adverse effects. Neostigmine (150 \( \mu \)g) caused mild nausea and 500-750 \( \mu \)g caused severe nausea and vomiting. Neostigmine (150-750 \( \mu \)g) produced subjective leg weakness, decreased deep tendon reflexes and sedation. The 750 \( \mu \)g dose was associated with anxiety, increased blood pressure and heart rate and decreased end-tidal carbon dioxide.

At the time, it seemed reasonable to test spinal neostigmine doses ranging from 50 to 200 \( \mu \)g, based on volunteers data. In mid-1996, the first prospective double-blind scientific study evaluated 50, 100, and 200 \( \mu \)g IT neostigmine to patients submitted to standardized general anesthesia for gynecological procedures by the vaginal route. This study confirmed data obtained with volunteers demonstrating dose-dependent analgesia, with peculiar adverse effects such as nystagmus, salivation, mydriasis and bradycardia not responding to intravenous atropine. In contrast, in volunteers who received only the administration of neostigmine by the IT route, the most prominent adverse effect was the occurrence of nausea and vomiting, which was later seen as anguish-producing and stressful for patients submitted to anesthesia by the regional route. The nausea and vomiting observed in volunteers depended on the dose used, on the baricity of the solution and on the method of administration. The cephalic ascension of the drug was apparently responsible for emesis. However, since the doses tested were high (50-750 \( \mu \)g), the initial false impression was that emesis resulted from the high doses, whereas doses in the 100-200 \( \mu \)g range administered to volunteers resulted in analgesia devoid of adverse effects. However, the differences observed at the time between volunteers and patients were intriguing. Specialists were aware of the fact that neostigmine caused analgesia and adverse effects, both of them dose dependent, but the potencies differed between these two populations. Studies on volunteers did not demonstrate analgesia with the administration of doses lower than 100 \( \mu \)g, whereas studies on patients demonstrated post-operative analgesia.
at lower doses. A multicenter study demonstrated dose-dependent analgesia and adverse effects when 25, 50, and 100 µg neostigmine were administered intrathecally to patients submitted to hysterectomy by the vaginal route. Similarly, 25, 50, and 75 µg IT neostigmine resulted in dose-dependent analgesia in patients submitted to orthopedic procedures under regional anesthesia.

This difference agreed with results observed in animals that demonstrated greater potency of IT neostigmine when the drug was administered in the presence of a surgical stimulus compared with the absence of pain. It was assumed that in the presence of a painful stimulus, the patients would have exacerbation of a cholinergic medullary pathway and therefore would not tolerate such high doses of neostigmine as volunteers not stimulated by a surgical act. Complementing this hypothesis, it was speculated that the ratio of the dose of IT neostigmine between patients and volunteers would be approximately 6 (ranging from 4 to 8) and it was inferred that 25-100 µg in patients would correspond to 150-750 µg in volunteers, being related to analgesia and adverse effects.

As an example of this theory, if only 750 µg caused analgesia in the hands of volunteers, we may assume that 125 µg neostigmine by the IT route would result in the same benefit in patients submitted to surgery of the upper limb.

### CLINICAL TRIALS

**Spinal neostigmine as part of multimodal analgesia**

This section is divided in the clinical reports where neostigmine was administered alone or in combination with other drugs through the spinal or epidural space (Table 1).

**Spinal neostigmine alone**

IT neostigmine (200, 100, and 50 µg) was initially evaluated in patients undergoing gynecologic surgeries under general anesthesia and demonstrated dose-dependent analgesia and adverse effects. Afterward, a prospective double-blind study demonstrated that the analgesic effect of spinal neostigmine diluted in saline was not equally effective for the different types of pain or for the different intensities of surgical stimuli. An investigation involving the qualitative evaluation of the analgesic actions of neostigmine administered by the IT route demonstrated that the drug was more effective for pain of the somatic type compared with pain of the visceral type and that intravenous administration of the anticholinergic agent N-butyl scopolamine acted peripherally as an effective complement for visceral pain, suggesting an association between the central cholinergic system and the peripheral anticholinergic system. The analgesic effect resulting from the peripheral anticholinergic drug was effective for visceral pain and might have reflected blockade of sympathetic ganglia through binding to nicotinic receptors, or a direct antispasmodic action on the viscera through an action on muscarinic receptors.

**Spinal neostigmine and local anesthetics**

A double-blinded study reported 6-9 h analgesia after 100 and 50 µg IT neostigmine in inguinal herniorrhaphy, with a high incidence of nausea and vomiting. In accordance, 50 and 25 µg neostigmine plus 10 mg hyperbaric bupivacaine for perianal surgery also demonstrate analgesia, emesis and prolonged motor blockade. Another study described 7 h of analgesia after the IV low dose ketamine combined with 50 µg IT neostigmine and bupivacaine in gynecologic surgeries, associated with a high incidence of emesis. In conformity, a study conducted on volunteers submitted to IT anesthesia with 7.5 mg bupivacaine in combination with 50, 12.5 or 6.25 µg neostigmine diluted in 5% glucose demonstrated that the incidence of nausea and vomiting was dose dependent and the duration of motor blockade was increased, limiting the use of this combination in ambulatory patients.

### Table 1: Analgesic effects of neostigmine

| Groups                        | IT neostigmine in patients | IT neostigmine in volunteers | Epidural neostigmine in patients |
|-------------------------------|-----------------------------|------------------------------|----------------------------------|
| Dose                          | Dose-dependent-1-300 µg     | Dose-dependent, 100-200 µg µg  | Dose dependent after doses >1 µg/kg |
| Potency                       | Greater potency in the presence of surgical stimuli | Lesser potency in the absence of surgical stimuli | Not evaluated |
| Type of pain                  | More effective for somatic rather visceral type of pain | Not evaluated | Not evaluated |
| Local anesthetics analgesia   | Enhanced | Not evaluated | Enhanced combined with sufentanil and ropivacaine |
| Opioid analgesia              | Enhanced | Not evaluated | Enhanced |
| Clonidine analgesia           | Enhanced | Not evaluated | Enhanced |
| Peripheral anticholinergic analgesia | Enhanced | Not evaluated | Enhanced |

IT: Intrathecal
Tan et al. evaluated IT 50 µg neostigmine compared to 300 µg morphine in patients submitted to knee arthrodesis. The study revealed the occurrence of 7 h of post-operative analgesia with the use of neostigmine, with greater patient satisfaction and a lower incidence of adverse effects. Using an open-label, dose-ranging design, patients undergoing cesarean section received either IT placebo or neostigmine 100, 30 and 10 µg solution of 5% glucose in normal saline followed by 2% epidural lidocaine for cesarean section. Compared with the glucose control, neostigmine produced a dose-independent reduction in post-operative morphine use and hourly morphine use was significantly reduced in the neostigmine groups for 10 h post-operatively, without adverse fetal or maternal effects. 5 µg IT neostigmine combined with bupivacaine resulted in a lower consumption of analgesics during the post-operative period and in 14 h of post-operative analgesia when combined with a skin patch with 5 mg nitroglycerin. No adverse effect was observed.

In children, it was assessed analgesia of spinal 0.25, 0.5, 0.75, and 1 µ/kg neostigmine added to bupivacaine for lower abdominal and urogenital procedures. Neostigmine at a dose of 0.75 µ/kg added to bupivacaine significantly prolonged spinal anesthesia duration with reduced post-operative pain scores and rescue analgesic requirements in infants undergoing lower abdominal and urogenital procedures and no additional benefits were provided on increasing it to 1 µ/kg.

**Spinal neostigmine and opioids**

A double-blinded study demonstrated that combined administration of 50 mg neostigmine and 50 µg morphine resulted in 23 h of effective analgesia in the study population. In patients submitted to abdominal hysterectomy, the combination of 25 µg neostigmine with 25 µg fentanyl given intrathecally with 15 mg of hyperbaric bupivacaine delayed post-operative pain and lowered the number of rescue analgesics in accordance to others who recently evaluated 25 µg neostigmine with 25 µg fentanyl in the lower abdominal surgery. A subsequent study assessed patients submitted to gynecologic surgeries by the abdominal route under spinal anesthesia with bupivacaine. The patients received combined administration of morphine and low doses of neostigmine for pain of the visceral type. The results revealed that the control patients obtained 3 h of post-operative analgesia, with a higher consumption of analgesics over a period of 24 h. The group that received only bupivacaine and morphine had 4 h of post-operative analgesia. However, the combination of 1, 2.5 or 5 µg neostigmine and morphine resulted in 8 h of analgesia, demonstrating the enhancement of the analgesic effect of morphine, with no increase in the incidence of adverse effects.

In accordance, Jain et al. described enhanced analgesia after 1 µg IT neostigmine combined to 20 µg fentanyl in total knee replacement surgery. The final analgesic effect may clinically reflect the importance of central cholinergic participation in the mediation of morphine nociception.

**Spinal neostigmine and clonidine**

A prospective study in cesarean section demonstrated that the combination of 50 µg neostigmine and 150 µg clonidine resulted in a prolongation of post-operative analgesia, although with a higher incidence of nausea and vomiting and motor blockade. The lower consumption of opioids would be explained by the exacerbation of the cholinergic tonus present during the painful stimulus in addition to the IT administration of neostigmine, with both events possibly resulting in increased concentrations of the neurotransmitter Ach in cerebrospinal fluid, present in mediation of the patients, shifting the curve of the response to IT sufentanil to the left.

**Spinal neostigmine in obstetrics**

Multimodal analgesia for the control of labor pain was also evaluated. One group of patients received 2.5 mg bupivacaine in combination with 25 µg IT fentanyl, while a second group additionally received 30 µg clonidine as a third drug and a third group received 10 µg neostigmine as the fourth drug. The addition of clonidine and neostigmine potentiated the analgesia of the first group, which however experienced a higher incidence of nausea. An experimental study demonstrated that IT neostigmine resulted in a greater potentiation of the α2-agonist clonidine compared with dexmedetomidine. The explanations proposed included the lower intrinsic potency of clonidine, which may be clinically enhanced by neostigmine, or the fact that the mechanism of action of dexmedetomidine may be less dependent on nitric oxide production. Another study conducted on patients revealed that the addition of 10 µg IT neostigmine reduced the affective analgesic dose by 25% in 50% (ED 50%) of the patients, shifting the curve of the response to IT sufentanil to the left.

**Epidural neostigmine as part of multimodal analgesia**

**Selection of doses to be evaluated by the epidural route**

Neostigmine is a hydrophilic molecule similar to morphine. It is known that only 10-20% of the morphine dose administered epidurally crosses the dura mater to reach the IT space, so that a 10 mg morphine dose administered epidurally is equivalent to 1 mg morphine administered.
The extrapolation of these data to the definition of the neostigmine dose to be evaluated by the epidural route followed logical reasoning: As demonstrated in reports published up to that time, the literature suggested that IT doses of 5 µg or 10 µg[73] might be effective as part of multimodal analgesia and the administration of ten times the dose of IT neostigmine might result in post-operative analgesia.[83] Consequently, the IT dose of 10 mg neostigmine would be equivalent to 100 µg neostigmine by the epidural route (or 2 µg/kg in a patient weighing 50 kg) and the IT dose of 5 µg neostigmine would be equivalent to the epidural dose of 1 µg/kg.[82]

**Epidural neostigmine alone**

Two studies published on this subject are concerned to children[83] and adults.[84] The double-blinded study evaluated 120 children scheduled for surgical repair of hypospadias under general anesthesia. Children were divided into groups and received either no caudal block or neostigmine in doses of 10, 20, 30, 40 and 50 µg/kg respectively at the end of the surgery. Caudal neostigmine alone in the dose range of 20-50 µg/kg provided dose-dependent analgesia. However, dose exceeding 30 µg/kg was associated with a higher incidence of nausea and vomiting.[83] Never in the literature, a patient received such a high dose of epidural neostigmine. Such a dose would be equivalent to 700-3500 µg in a median 70-kg adult patient, more than ten-fold the safe tested dose used in adults, described by others.[85]

In the second study, epidural 4 or 8 µg/kg were infused epidurally diluted with saline under combined spinal anesthesia with lidocaine. The authors described that analgesia after the preemptive administration of epidural 8 µg/kg at 12 and 24 h compared with the other groups with no side-effects.[84]

**Epidural neostigmine and local anesthetics**

Studies on acute pain assessing the administration of neostigmine by the epidural route started in orthopedic surgery. Patients submitted to knee surgeries received saline or 1, 2 or 4 µg/kg neostigmine, diluted in 1% lidocaine, by the epidural route in a combined anesthetic technique involving spinal anesthesia/epidural analgesia.[82] The results demonstrated 8 h of post-operative analgesia regardless of the dose, with no adverse effects.[83] The local anesthetic lidocaine has been demonstrated to suppress different pain conditions when administered systemically, and part of the antinociceptive effect of systemic lidocaine appears to be mediated via muscarinic and nicotinic receptors.[86] Consequently, epidural lidocaine could also be partially systemically absorbed and enhance epidural neostigmine analgesia.

A different study evaluated epidural lidocaine alone or combined with epidural neostigmine (100 and 200 µg). The addition of neostigmine resulted in significant longer duration of analgesia (dose independent) and sedation (dose dependent). Sensory and motor blockade were identical in all three groups. The authors considered useful analgesia and desirable sedation.[87]

**Genitourinary procedures in children**

Genitourinary procedures in children demonstrated no efficacy of 1 µg/kg caudal neostigmine mixed with bupivacaine.[88] However, a single caudal injection of 2 µg/kg neostigmine added to ropivacaine offered an advantage over ropivacaine alone for pain relief in children undergoing genitourinary surgery.[89] Another study demonstrated that caudal neostigmine (2, 3 and 4 µg/kg) with bupivacaine produced a dose-independent analgesic effect (16-17 h) and a reduction in post-operative rescue analgesic consumption without increasing the incidence of adverse effects.[90] Another research group evaluated the post-operative analgesic action of high doses of epidural neostigmine and reported that 10 µg/kg, but not 5 µg/kg, resulted in 6 h of analgesia in patients submitted to hysterectomy. The patients did not experience emesis and were submitted to general anesthesia in combination with epidural blockade,[91] nevertheless, sedation was not evaluated.

A total of 80 patients undergoing elective cesarean were given combined spinal-epidural anesthesia with 8 mg hyperbaric bupivacaine plus 10 µg fentanyl. Patients were randomized to receive either saline or 75, 150, or 300 µg neostigmine in 10 ml saline after cord clamping. Global pain assessment for the first 24 h was reduced from 5.4 in the saline group to 3.5 in the neostigmine groups. Nausea and morphine consumption were similar among groups. Intraoperative shivering and sedation were increased in the 300 µg neostigmine group only and post-operative sedation was increased by neostigmine in a dose-independent fashion suggesting a limited role for single bolus-administration epidural neostigmine for analgesia after cesarean delivery.[83]

Finally, 60 patients undergoing below umbilical surgeries under epidural anesthesia received 20 ml of 0.5% bupivacaine with either 1 ml of normal saline, 100 µg of neostigmine or 50 mg of ketamine. Both neostigmine and ketamine demonstrated better hemodynamic stability with lesser incidence of hypotension and better analgesia.[92]

**Epidural neostigmine and opioids**

The combined administration of low doses of morphine and neostigmine by the epidural route was subsequently evaluated.[93] 60 µg neostigmine and 0.6 mg morphine, both administered epidurally, resulted in 11 h of post-operative analgesia in orthopedic surgeries, with no adverse effects.[94] In accordance, a prospective double-blind study concerning
Epidural neostigmine in obstetrics

Labor, a model of acute pain involving both somatic and visceral pain types revealed no benefit (but no side-effects) off adding 4 µg/kg epidural neostigmine to the mixture 100 mg ropivacaine/10 µg sufentanil,[93] however similar duration of analgesia following 6-7 µg/kg epidural neostigmine combined with 10 mg sufentanil compared to epidural 20 µg sufentanil[90] and further demonstrated that the inclusion of 60 mg lidocaine with epinephrine epidural test dose would affect ambulation in earlier labor.[97]

Prior to 2009, studies examined only single epidural neostigmine bolus administration and did not assess the efficacy of continuous epidural infusion or several aspects of maternal and fetal safety. After then, new data was available concerning epidural neostigmine efficacy and safety for both fetus and mother. A total of 12 healthy women scheduled for elective cesarean delivery were assigned to receive epidural neostigmine 40 or 80 µg/kg while IL-6 was not affected during lower open abdominal.[85] Continuous thoracic epidural neostigmine was evaluated in thoracotomy. The epidural dose of 500 µg bolus followed by 125 µg/h provided preemptive analgesia and an analgesic-sparing effect that improved post-operative analgesia for these patients without increasing the incidence of adverse effects.[102]

ADVERSE EFFECTS

Adverse effects are summarized in Table 2.

Spinal neostigmine

IT neostigmine increased incidence of nausea and vomiting, bradycardia requiring intravenous atropine, anxiety, agitation, or restlessness. It did not affect the duration of motor blockade.

Table 2: Adverse effects of IT and epidural neostigmine

| Groups          | IT neostigmine in patients | IT neostigmine in volunteers | Epidural neostigmine in patients |
|-----------------|----------------------------|------------------------------|----------------------------------|
| Nausea/vomiting| Dose-dependent, severe, minimum at doses <5 µg, enhanced by IV opioids[76] | Mild nausea after 150 µg, severe nausea after 500 and 750 µg, dependent on the baricity[51] | Not significant at doses <30 µg/kg[86] |
| Motor block     | Prolonged bupivacaine motor block[55,60,69] divergence in other studies[56,67,71] | Subjective leg weakness, decreased deep tendon reflexes after 150-750 µg[81] | None |
| Bradycardia     | After 200 µg, not reversed by atropine[92] | None                          | None |
| Tachycardia     | None                        | After 750 µg[81]              | None |
| Hypertension    | None at doses up to 200 µg[71] | After 750 µg[81]              | 100 mg-better haemodynamic stability, lesser hypotension[71] |
| Sedation        | None described (doses ranging 1-200 µg) | None                          | Increased at doses 100-200 µg[85] or >300 µg[90] |
| Anxiety         | None                        | After 750 µg[81]              | None |

IT: Intrathecal
or the total amount of ephedrine required.\textsuperscript{103} The nausea and vomiting observed in volunteers after spinal neostigmine were dependent on the dose used, on the baricity of the solution and on the method of administration and the cephalic ascension of the drug was apparently responsible for emesis.\textsuperscript{13} Emesis secondary to IT neostigmine used to be difficult to treat in awake or lightly sedated patients and exacerbated by the combination of opioids injected intravenously, but not when they were injected intrathecally.\textsuperscript{71}

Other studies that were conducted to assess the efficacy of different antiemetic drugs in the control of nausea and vomiting characterized emesis as being more intense after manipulation of intra-abdominal viscera\textsuperscript{57} compared to orthopedic procedures (somatic type of pain),\textsuperscript{58} but not responsive to intravenous droperidol (500 mg), metoclopramide (10 mg),\textsuperscript{57,58} ondansetron (4 mg),\textsuperscript{65} or dexamethasone (10 mg).\textsuperscript{106} The only effective drug seems to be intravenous propofol (2-4 mg/kg/h), but only during the period of infusion,\textsuperscript{57,58} secondary to the intrinsic antiemetic property of propofol at sub-hypnotic doses.\textsuperscript{106} A possible sedative effect may have reduced the sensation of nausea.\textsuperscript{106}

**Epidural neostigmine**

Administration of neostigmine by the epidural route would be mainly characterized by the action of enzymes located in the meninges,\textsuperscript{13,12} with low participation at spinal sites.\textsuperscript{113} Until date, epidural doses exceeding 30 µg/kg were associated with a higher incidence of nausea and vomiting\textsuperscript{84} and post-operative sedation was increased after 300 µg epidural neostigmine following cesarean delivery.\textsuperscript{73}

**Anti-hypotensive action of spinal neostigmine**

Continued efforts were made in order to assess another possible property of spinal neostigmine, i.e., the ability of the drug to antagonize the hypotensive action secondary to IT anesthesia. In 1994, a study on sheep suggested that hypotension secondary to the administration of a α2-agonist may be prevented by the stimulation of M2 spinal muscarinic cholinergic receptors and by nitric oxide synthesis.\textsuperscript{107} It would be extremely interesting and clinically applicable if the drug could minimize the hypotension resulting from regional blockade with a local anesthetic, as demonstrated in rats\textsuperscript{108} in addition to providing post-operative analgesia.

Unfortunately, because of emesis, the doses that could be used in patients were limited and did not reduce the occurrence of hypotension in patients submitted to regional anesthesia with bupivacaine.\textsuperscript{109} Studies on sheep\textsuperscript{110} clarified that the difference observed between the results obtained with rats and with patients were probably due to the larger size and consequent lower exposure of the spinal cord of the patients proportionally compared with the size of the spinal cord of small animals.\textsuperscript{108,110}

**CONCLUSIONS**

When one analyze the past two decades, IT doses of neostigmine in humans ranged from 750 to 1 µg. Due to side-effects the dose was substantially decreased. Because of the small doses, neostigmine should be applied only as part of multimodal spinal analgesia, and further clinical trials are still needed. Conversely, epidural neostigmine may be evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects. Future studies may also include formulations containing liposomes using technology of gradual neostigmine release.\textsuperscript{111}

Based on the present data, IT neostigmine dose related efficacy and safety is better approached in patients with spinal doses less than 10 µg, while epidural neostigmine can afford to trials with different doses due to the apparent lack of side effects.

**REFERENCES**

1. Pellandra CL. The morphine geneserine adjuvants of general anesthesia. Lyon Med 1933;157:653-7.
2. Kremer M. Action of intrathecally injected prostigmine acetylcholine, and eserine on the central nervous system in man. J Exp Physiol 1942;31:337-57.
3. Flodmark S, Wrammer T. The analgesic action of morphine, eserine and prostigmine studied by a modified Handy-Wolff-Good method. Acta Physiol Scand 1994;9:88-96.
4. Pleuvry BJ, Tobias MA. Comparison of the antinociceptive activities of physostigmine, oxtremorine and morphine in the mouse. Br J Pharmaco 1971;43:706-14.
5. Nistri A, Pepeu G, Cammelli E, Spina L, De Bellis AM. Effects of morphine on brain and spinal acetylcholine levels and nociceptive threshold in the frog. Brain Res 1974;80:199-209.
6. Wamsley JK, Lewis MS, Young WS 3rd, Kuhar MJ. Autoradiographic localization of muscarinic cholinergic receptors in rat brainstem. J Neurosci 1981;1:176-91.
7. Fakhs TL, Dirsken R, Harty GJ. Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmaco 1985;117:81-8.
8. Peterson I, Gobd TF, Hartvig P, Wiklund L. A double-blind trial of the analgesic properties of physostigmine in postoperative patients. Acta Anaesthesiol Scand 1986;30:283-8.
9. Fakhs TL, Grafe MR, Maunus S, Rathburn ML, Eisenach JC. Studies on the safety of chronically administered intrathecal neostigmine methylsulfate in rats and dogs. Anesthesiology 1995;82:412-27.
10. Fakhs DD, Eisenach JC, Tong C, Tommasi E, Fakhs TL. Cardiorespiratory and spinal cord blood flow effects of intrathecal neostigmine methylsulfate, clonidine, and their combination in sheep. Anesthesiology 1995;82:428-35.
11. Werdehausen R, Braun S, Herrmans H, Kremer D, Kury P, Hollmann M, et al. The influence of adjuvants used in regional anesthesia on lidocaine-induced neurotoxicity in vitro. Reg Anesth Pain Med 2011;36:436-43.
12. Gurun MS, Leinbach R, Moore L, Lee CS, Owen MD, Eisenach JC. Studies on the safety of glucose and paraben-containing neostigmine for intrathecal administration. Anesth Analg 1997;85:317-23.
13. Hood DD, Eisenach JC, Tuttle R. Phase I safety assessment of intrathecal neostigmine methysulfate in humans. Anesthesiology 1995;82:331-43.

14. Hood DD, Mallak KA, Eisenach JC, Tong C. Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. Anesthesiology 1996;85:315-25.

15. Klamt JG, Dos Reis MP, Barbieri Neto J, Prado WA. Analgesic effect of subarachnoid neostigmine in two patients with cancer pain. Pain 1996;66:389-91.

16. Lauretti GR, Gomes JM, Reis MP, Pereira NL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 1999;11:663-8.

17. Shafer SL, Eisenach JC, Hood DD, Tong C. Cerebrospinal fluid pharmacokinetics and pharmacodynamics of intrathecal neostigmine methysulfate in humans. Anesthesiology 1998;89:1074-88.

18. Honda K, Harada A, Takano Y, Kamiya H. Involvement of M3 muscarinic receptors of the spinal cord in formalin-induced nociception in mice. Brain Res 2000;859:38-44.

19. Duttaroy A, Gomez J, Gan JW, Siddiqui N, Basile AS, Harman WD, et al. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 2002;62:1084-93.

20. Chen SR, Pan HL. Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. Anesthesiology 2001;95:525-30.

21. Vincler M, Eisenach JC. Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation. Neurosci Res 2004;48:139-45.

22. Genzen JR, Van Cleve W, McGeehe DS. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. J Neurophysiol 2001;86:1773-82.

23. Thomsen MS, Mikkelsen JD. The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia. J Neuroimmunol 2012;251:65-72.

24. Umeda E, Aramaki Y, Mori T, Kazama T. Muscarinic receptor subtypes modulate the release of [3H]-noradrenaline in rat spinal cord slices. Brain Res Bull 2006;70:99-102.

25. Rashid MH, Furue H, Yoshimura M, Ueda H. Tonic inhibitory role of alpha4 beta2 subtype of nicotinic acetylcholine receptors on nociceptive transmission in the spinal cord in mice. Pain 2006;125:125-35.

26. Yoon SY, Kwon YB, Kim HW, Roh DH, Seo HS, Han HJ, et al. A spinal muscarinic M2 receptor-GABAergic disinhibition pathway that modulates peripheral inflammation in mice. Neuropharmacology 2007;53:677-86.

27. Schechtmann G, Song Z, Uitenius C, Meyerson BA, Linderoth B. Cholinergic mechanisms involved in the pain relieving effect of spinal cord stimulation in a model of neuropathy. Pain 2008;139:136-45.

28. Chiar i A, Tobin JR, Pan HL, Hood DD, Eisenach JC. Sex differences in cholinergic analgesia I: A supplemental nicotinic mechanism in normal females. Anesthesiology 1999;91:1447-54.

29. Lavand’homme PM, Eisenach JC. Sex differences in cholinergic analgesia II: Differing mechanisms in two models of allodynia. Anesthesiology 1999;91:1455-61.

30. Damaj MI. Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. J Pharmacol Exp Ther 2001;296:132-40.

31. Kring JS, Buvanendran A, Nagalla SK, Tuman KJ. Postoperative pain and analgesic responses are similar in male and female Sprague-Dawley rats. Can J Anaesth 2003;50:904-8.

32. Bouaziz H, Tong C, Eisenach JC. Postoperative analgesia from intrathecal neostigmine in sheep. Anesth Analg 1995;80:1-5.

33. Baba H, Kohno T, Okamoto M, Goldstein PA, Shimoji K, Yoshimura M. Muscarinic facilitation of GABA release in substantia gelatinosa of the rat spinal dorsal horn. J Physiol 1998;508:83-93.

34. Chen SR, Pan HL. Activation of muscarinic receptors inhibits spinal dorsal horn projection neurons: Role of GABAB receptors. Neuroscience 2004;125:141-8.

35. Chen SR, Pan HL. Spinal GABAB receptors mediate antinociceptive actions of cholinergic agents in normal and diabetic rats. Brain Res 2003;965:67-74.

36. Smith MD, Yang XH, Nha JY, Buccafusco JJ. Antinociceptive effect of spinal cholinergic stimulation: Interaction with substance P. Life Sci 1989;45:1255-61.

37. Dunbar SA, Karamian IG. Cross-tolerance between spinal neostigmine and morphine in the rat. Br J Anaesth 2001;91:427-9.

38. Saki S, Kakishita M, Nakamura T, Kobayashi T, Ogawa S. The effects of intrathecally administered neostigmine on somato-sympathetic reflex potentials. Masui 2002;51:1322-30.

39. Prado WA, Gonçalves AS. Antinociceptive effect of intrathecal neostigmine evaluated in rats by two different pain models. Braz J Med Biol Res 1997;30:1225-31.

40. Detweiler DJ, Eisenach JC, Tong C, Jackson C. A cholinergic interaction in alpha 2 adrenoceptor-mediated antinociception in sheep. J Pharmacol Exp Ther 1993;265:536-42.

41. Bouaziz H, Hewitt C, Eisenach JC. Subarachnoid neostigmine potentiation of alpha 2-adrenergic agonist analgesia. Dexametomidine versus clonidine. Reg Anesth 1995;20:121-7.

42. Hwang JH, Hwang KS, Kim JU, Choi IC, Park PH, Han SM. The interaction between intrathecal neostigmine and GABA receptor agonists in rats with nerve ligation injury. Anesth Analg 2001;93:1297-303.

43. Winne RP, Abram SE. Intrathecal morphine and neostigmine produce synergistic analgesia to noxious thermal stimuli in rats. Reg Anesth 1994;19:2-6.

44. Yoon MH, Choi JI, Kwak SH. Characteristic of interactions between intrathecal gabapentin and either clonidine or neostigmine in the formalin test. Anesth Analg 2004;98:1374-9.

45. Miranda HF, Sierralta F, Pinardi G. Neostigmine interactions with non steroidal anti-inflammatory drugs. Br J Pharmacol 2002;135:1591-7.

46. De Angelis F, Bernardo A, Magnaghi V, Minghetti L, Tata AM. Muscarinic receptor subtypes as potential targets to modulate opioidergic neurotransmission. J Pharm Pharmacol 1999;51:1073-81.

47. Craig HJ. Anaesthetic gases. In: Dundee JW, Clarke RS, editors. Clinical Anesthetic Pharmacology. New York: Churchill Livingstone; 1990. p. 127-36.

48. Ummenhofer WC, Brown SM, Bernards CM. Acetylcholinesterase esterase containing nerves of cranial and spinal dura mater in humans and rodents. Microsc Res Tech 2001;53:212-20.

49. Buvanendran A, Kroin JS, Kems JM, Nagalla SN, Tuman KJ. Characterization of a new animal model for evaluation of persistent postthoracotomy pain. Anesth Analg 2004;99:1453-60.

50. Salamone G, Lombardi G, Gori S, Nahmod K, Jancic C, Amaral MM, et al. Cholinergic modulation of dendritic cell function. J Neuroimmunol 2011;236:47-56.

51. Lauretti GR, de Oliveira R, Perez MV, Paccola CA. Postoperative analgesia by intraarticular and epidural neostigmine following knee surgery. J Clin Anesth 2000;12:444-8.

52. Ummenhofer WC, Brown SM, Bernards CM. Acetylcholinesterase and butyrylcholinesterase are expressed in the spinal meninges of monkeys and pigs. Anesthesiology 1998;88:1259-65.

53. Araujo RMC, Cavallotti C, Catecholaminergic and acetylcholine esterase containing nerves of cranial and spinal dura mater in humans and rodents. Microsc Res Tech 2001;53:212-20.

54. Craig HJ. Anaesthetic gases. In: Dundee JW, Clarke RS, McCaughey W, editors. Clinical Anesthetic Pharmacology, New York: Churchill Livingstone; 1990. p. 127-36.

55. Lin X, Wang Q, Huang W, Zhu L, Yang B. Study on the mechanism of antinociception of intrathecal neostigmine in...
the formalin test in rats. Sichuan Da Xue Xue Bao Yi Xue Ban 2003;34:698-700.

56. Lauretti GR, Reis MP, Prado WA, Klamt JG. Dose-response study of intrathecal morphine versus intrathecal neostigmine, their combination, or placebo for postoperative analgesia in patients undergoing anterior and posterior vaginoplasty. Anesth Analg 1996;82:1182-7.

57. Lauretti GR, Mattos AL, Gomes JM, Pereira NL. Postoperative analgesia and antieptic efficacy after intrathecal neostigmine in patients undergoing abdominal hysterectomy during spinal anesthesia. Reg Anesth 1997;22:527-33.

58. Lauretti GR, Reis MP. Postoperative analgesia and antieptic efficacy after subarachnoid neostigmine in orthopedic surgery. Reg Anesth 1997;22:337-42.

59. Lauretti GR, Hood DD, Eisenach JC, Pfeifer BL. A multi-center study of intrathecal neostigmine for analgesia following vaginal hysterectomy. Anesthesiology 1998;89:913-8.

60. Lauretti GR, Mattos AL, Reis MP, Prado WA. Intrathecal neostigmine for postoperative analgesia after orthopedic surgery. J Clin Anesth 1997;9:473-7.

61. Lauretti GR. The clinical use of intrathecal neostigmine in regional anesthesia. LASRA Journal 1997;2:2-3.

62. Lauretti GR, Lima IC. The effects of intrathecal neostigmine on somatic and visceral pain: Improvement by association with a peripheral anticholinergic. Anesth Analg 1996;82:617-20.

63. Tan P-H, Kuo J-H, Liu K, Hung C-C, Tsai TC, Deng TY. Efficacy of intrathecal neostigmine for the relief of postinguinal hemiorrhapsy pain. Acta Anaesthesiol Scand 2000;44:1056-60.

64. Yegin A, Yilmaz M, Karali B, Erman M. Analgesic effects of intrathecal neostigmine in perianal surgery. Eur J Anaesthesiol 2003;20:404-8.

65. Lauretti GR, Azevedo VM. Intravenous ketamine or fentanyl prolongs postoperative analgesia after intrathecal neostigmine. Anesth Analg 1996;83:766-70.

66. Liu SS, Hodgson PS, Moore JM, Trautman WJ, Burkhead DL. Dose-response effects of spinal neostigmine added to bupivacaine spinal anesthesia in volunteers. Anesthesiology 1999;90:710-7.

67. Tan PH, Chia YY, Lo Y, Liu K, Yang LC, Lee TH. Intrathecal bupivacaine with morphone or neostigmine for postoperative analgesia after total knee replacement surgery. Can J Anaesthet 2001;48:551-6.

68. Krzynowek JA, Hood DD, Eisenach JC, Mallak KA, Parker RL. Intrathecal neostigmine for post-caesarean section analgesia: Dose response. Anesth Analg 1997;84:1269-75.

69. Lauretti GR, Oliveira AP, Juliao MC, Reis MP, Pereira NL. Transdermal nitroglycerine enhances spinal neostigmine postoperative analgesia following gynecologic surgery. Anesthesiology 2002;93:943-6.

70. Batra YK, Rajeev S, Panda NB, Lokesh VC, Rao KL. Intrathecal neostigmine with bupivacaine for infants undergoing lower abdominal and urogenital procedures: Dose response. Acta Anaesthesiol Scand 2003;53:470-5.

71. Lauretti GR, Mattos AL, Reis MP, Pereira NL. Combined intrathecal fentanyl and neostigmine: Therapy for postoperative abdominal hysterectomy pain relief. J Clin Anesth 1998;10:291-6.

72. Akinwale MO, Sotunmbi PT, Akinyemi OA. Analgesic effect of intrathecal neostigmine combined with bupivacaine and fentanyl. Afr J Med Sci 2012;41:231-7.

73. Almeida RA, Lauretti GR, Mattos AL. Antinociceptive effect of low-dose intrathecal neostigmine combined with intrathecal morphine following gynecologic surgery. Anesthesiology 2003;98:495-8.

74. Jain A, Jain K, Bhardwaj N. Analgesic efficacy of low-dose intrathecal neostigmine in combination with fentanyl and bupivacaine for total knee replacement surgery. J Anaesthesiol Clin Pharmaco 2012;28:486-90.

75. Pan PM, Huang CT, Wei TT, Mok MS. Enhancement of analgesic effect of intrathecal neostigmine and clonidine on bupivacaine spinal anesthesia. Reg Anesth Pain Med 1998;23:49-56.

76. Dirksen R, Nijhuis GM. The relevance of cholinergic transmission at the spinal level to opiate effectiveness. Eur J Pharmacol 1983;91:215-21.

77. Hood DD, Mallak KA, James RL, Tuttle R, Eisenach JC. Enhancement of analgesia from systemic opioid in humans by spinal cholinesterase inhibition. J Pharmacol Exp Ther 1997;282:86-92.

78. D’Angelo R, Dean LS, Meister GC, Nelson KE. Neostigmine combined with bupivacaine, clonidine, and sufentanil for spinal labor analgesia. Anesth Analg 2001;93:1534-8.

79. Omer MD, Ozerar O, Sahin S, Ucukkaya N, Kaplan N, Memis I, Low-dose clonidine and neostigmine prolong the duration of intrathecal bupivacaine-fentanyl for labor analgesia. Anesthesiology 2000;92:361-6.

80. Nelson KE, D’Angelo R, Foss ML, Meister GC, Hood DD, Eisenach JC. Intrathecal neostigmine and sufentanil for early labor analgesia. Anesthesiology 1999;91:1293-8.

81. Watson PJ, Moore RA, McQuay HJ. Plasma morphine concentrations and analgesic effects of lumbar extradural morphine and heroin. Anesth Analg 1984;63:629-34.

82. Lauretti GR, de Oliveira R, Reis MP, Juliao MC, Pereira NL. Study of three different doses of epidural neostigmine coadministered with lidocaine for postoperative analgesia. Anesthesiology 1999;90:1534-8.

83. Batra YK, Arya VK, Mahajan R, Chari P. Dose response study of caudal neostigmine for postoperative analgesia in paediatric patients undergoing gynoirnitory surgery. Paediatr Anaesth 2003;13:515-21.

84. Taspinar V, Pala Y, Diker S, Ornek HD, Ozdogan L, Akcay M, et al. Pre-emptive analgesic and haemodynamic efficacy of combined spinal-epidural neostigmine delivery. J Coll Physicians Surg Pak 2012;22:201-6.

85. Kaya FN, Sahin S, Owen MD, Eisenach JC. Epidural neostigmine produces analgesia but also sedation in women after cesarean delivery. Anesthesiology 2004;100:381-5.

86. Abelson KS, Höglund AU. Intravenously administered lidocaine in therapeutic doses increases the intraspinal release of acetylcholine in rats. Neurosci Lett 2002;317:93-6.

87. Harjai M, Chandra G, Bhatia VK, Singh D, Bhaskar P. A comparative study of two different doses of epidural neostigmine coadministered with lignocaine for post operative analgesia and sedation. J Anaesthesiol Clin Pharmac 2010;26:461-4.

88. Memis D, Duran A, Karamanlioglu B, Kaya G, Sut N, Pamukcu Z. Caudal neostigmine for postoperative analgesia in paediatric surgery. Paediatr Anaesth 2003;13:324-8.

89. Duran A, Memis D, Basaran UN, Karamanlioglu B, Sut N. Caudal ropivacaine and neostigmine in pediatric surgery. Paediatr Anaesth 2003;13:720-7.

90. Nakayama M, Ichinose H, Nakabayashi K, Sato O, Yamamoto S, Namiki A. Analgesic effect of epidural neostigmine after abdominal hysterectomy. J Clin Anesth 2001;13:86-9.

91. Dadu S, Misra LS, Agrawal M, Chandola HC. Comparative clinical study of effect of neostigmine and ketamine for postoperative analgesia. J Indian Med Assoc 2011;109:308-11.

92. Omais M, Lauretti GR, Paccola CA. Epidural morphine and neostigmine for postoperative analgesia after orthopedic surgery. Anesth Analg 2002;95:762-6.

93. Lauretti GR, Azevedo VM, Lopes BC, Mattos AL. Comparison between the intravenous and caudal route of sufentanil in children undergoing orthopedectomy. Further evaluation of the association of caudal adrenaline and neostigmine. Saudi J Anaesth 2014;8:345-50.

94. Roelants F, Rizzo M, Lavand’homme P. The effect of epidural neostigmine combined with ropivacaine and sufentanil on neuraxial analgesia during labor. Anesth Analg 2003;96:1161-6.
96. Roelants F, Lavand’homme PM. Epidural neostigmine combined with sufentanil provides balanced and selective analgesia in early labor. Anesthesiology 2004;101:439-44.

97. Roelants F, Mercier-Fuzier V, Lavand’homme PM. The effect of a lidocaine test dose on analgesia and mobility after an epidural combination of neostigmine and sufentanil in early labor. Anesth Analg 2006;103:1534-9.

98. Ross VH, Pan PH, Owen MD, Seid MH, Harris L, Clyne B, et al. Neostigmine decreases bupivacaine use by patient-controlled epidural analgesia during labor: A randomized controlled study. Anesth Analg 2009;109:524-31.

99. Van de Velde M, Berends N, Kumar A, Devroe S, Devlieger R, Vandermeersch E, et al. Effects of epidural clonidine and neostigmine following intrathecal labour analgesia: A randomised, double-blind, placebo-controlled trial. Int J Obstet Anesth 2009;18:207-14.

100. Kirdemir P, Ozkoçak I, Demir T, Gögüş N. Comparison of postoperative analgesic effects of preemptively used epidural ketamine and neostigmine. J Clin Anesth 2000;12:543-8.

101. Masaki E, Saito H, Shoji K, Matsushima M. Postoperative analgesic effect of epidural neostigmine and plasma cortisol and IL-6 responses. J Clin Anesth 2004;16:488-92.

102. Chia YY, Chang TH, Liu K, Chang HC, Ko NH, Wang YM. The efficacy of thoracic epidural neostigmine infusion after thoracotomy. Anesth Analg 2006;102:201-8.

103. Ho KM, Ismail H, Lee KC, Branch R. Use of intrathecal neostigmine as an adjunct to other spinal medications in perioperative and peripartum analgesia: A meta-analysis. Anaeseth Intensive Care 2005;33:41-53.

104. Tan PH, Liu K, Peng CH, Yang LC, Lin CR, Lu CY. The effect of dexamethasone on postoperative pain and emesis after intrathecal neostigmine. Anesth Analg 2001;92:228-32.

105. Borgeat A, Wilder-Smith OH, Saiaf K. Subhypnotic doses of propofol possess direct antiemetic properties. Anesth Analg 1992;74:539-41.

106. Hvarfner A, Hammas B, Thörn SE, Wattwil M. The influence of propofol on vomiting induced by apomorphine. Anesth Analg 1995;80:967-9.

107. Lothe A, Li P, Tong C, Yoon Y, Bouaziz H, Detweiler DJ, et al. Spinal cholinergic alpha-2 adrenergic interactions in analgesia and hemodynamic control: Role of muscarinic receptor subtypes and nitric oxide. J Pharmacol Exp Ther 1994;270:1301-6.

108. Carp H, Jayaram A, Morrow D. Intrathecal cholinergic agonists lessen bupivacaine spinal-block-induced hypotension in rats. Anesth Analg 1994;79:112-6.

109. Lauretti GR, Reis MP. Subarachnoid neostigmine does not affect blood pressure or heart rate during bupivacaine spinal anesthesia. Reg Anesth 1996;21:586-91.

110. Rose G, Xu Z, Tong C, Eisenach JC. Spinal neostigmine diminishes, but does not abolish, hypotension from spinal bupivacaine in sheep. Anesth Analg 1996;83:1041-5.

111. Grant GJ, Piskoun B, Bansinath M. Intrathecal administration of liposomal neostigmine prolongs analgesia in mice. Acta Anaesthesiol Scand 2002;46:90-4.

How to cite this article: Lauretti GR. The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades. Saudi J Anaesth 2015;9:71-81.

Source of Support: Nil, Conflict of Interest: None declared.